Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Amyris to Perform

Oppenheimer Downgrades Amyris to Perform

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

Cybin Inc. Announces First Participants Dosed In Its Phase 1/2a Trial Of CYB003 For The Treatment Of Major Depressive Disorder

By Benzinga Newsdesk

August 30, 8:10 AM

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first

CYBN

Walgreens Reportedly Confronts Impending Staff Walkout — Is Your Local Pharmacy Shutting Down Next Week?

By Nabaparna Bhattacharya

October 7, 5:24 PM

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) employees, including pharmacists, technicians, and support staff, are reportedly gearing up for a

WBA

Analyst Ratings

Where Hudson Pacific Properties Stands With Analysts

By Benzinga Insights

September 9, 11:11 AM

Hudson Pacific Properties (NYSE:HPP) has observed the following analyst ratings within the last quarter:

HPP

Tencent Bounces Back On Growth Lane In Q1, Posts Strong Sales Round

By Lekha Gupta

May 18, 7:15 AM

Yesterday, Tencent Holdings Ltd (OTC:TCEHY) reported a Q1 2023 revenue increase of 11% Y/Y to ¥150 billion ($21.8 billion). The company…

TCEHY

Oppenheimer Downgrades Amyris to Perform

Related Posts

Cybin Inc. Announces First Participants Dosed In Its Phase 1/2a Trial Of CYB003 For The Treatment Of Major Depressive Disorder

Walgreens Reportedly Confronts Impending Staff Walkout — Is Your Local Pharmacy Shutting Down Next Week?

Where Hudson Pacific Properties Stands With Analysts

Tencent Bounces Back On Growth Lane In Q1, Posts Strong Sales Round